Despite this promising result, the combination therapy did not meet the primary endpoint (CR rate) in a phase 3 clinical trial for patients with TP53-mutated MDS, though the CR rate tended to be superior in the combination group than the azacitidine monotherapy group (33.3% vs. 22.4%) [92]. This evidence concerns the gene TP53 and myelodysplastic syndrome.